BioSyent Inc. (CVE:RX - Get Free Report)'s share price crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$11.20 and traded as low as C$11.05. BioSyent shares last traded at C$11.10, with a volume of 1,686 shares trading hands.
BioSyent Price Performance
The company has a debt-to-equity ratio of 2.90, a quick ratio of 6.91 and a current ratio of 3.92. The firm has a fifty day simple moving average of C$11.17 and a two-hundred day simple moving average of C$11.03. The firm has a market cap of C$126.61 million, a PE ratio of 17.97 and a beta of 0.93.
Insider Buying and Selling
In related news, insider FAX Capital Corp. sold 112,400 shares of the firm's stock in a transaction on Monday, December 23rd. The stock was sold at an average price of C$11.28, for a total value of C$1,267,557.28. Also, Senior Officer Robert Joseph March sold 4,775 shares of the business's stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of C$11.65, for a total value of C$55,628.75. Over the last 90 days, insiders have sold 117,707 shares of company stock worth $1,329,581. Insiders own 33.65% of the company's stock.
BioSyent Company Profile
(
Get Free Report)
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
Read More
Before you consider BioSyent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.
While BioSyent currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
